Copyright 2009 Medical News Today Latest Cholesterol News From Medical News Today. http://www.medicalnewstoday.com/sections/cholesterol/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Sun, 05 Jul 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/156262.php http://www.medicalnewstoday.com/articles/156262.php Tekmira Pharmaceuticals Corporation (TSX:TKM) announced that it has initiated a Phase 1 human clinical trial for ApoB SNALP. ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a treatment for patients with elevated low-density lipoprotein (LDL) cholesterol, or "bad" cholesterol, who are not well served by current therapy. Cholesterol Thu, 25 Jun 2009 03:00:00 PDT http://www.medicalnewstoday.com/articles/155270.php http://www.medicalnewstoday.com/articles/155270.php New research from two Philadelphia-area cardiologists finds that an over-the-counter dietary supplement sold at pharmacies and health food stores may be an alternative for patients who cannot take traditional statin medications to lower cholesterol because of statin-related muscle pain. The findings of their study, "Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients," appear in the June 16, 2009 issue of Annals of Internal Medicine. Cardiologists David Becker, M. Cholesterol Thu, 18 Jun 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/154320.php http://www.medicalnewstoday.com/articles/154320.php Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, announced final data from three separate Phase II trials involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein inhibitor (MTP-I) small molecule drug. Cholesterol Wed, 17 Jun 2009 03:00:00 PDT http://www.medicalnewstoday.com/articles/154196.php http://www.medicalnewstoday.com/articles/154196.php New data presented showed that pitavastatin is an effective treatment for the management of dyslipidemia in elderly patients, with a similar safety and tolerability profile to low-dose pravastatin. The Phase III data were presented by Kowa, at the XV International Symposium on Atherosclerosis in Boston. Endocrinology Wed, 17 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/154166.php http://www.medicalnewstoday.com/articles/154166.php Calcium Supplementation Has No Weight-loss Benefit for Obese Patients One in three American adults is overweight or obese, with a body mass index (BMI) of 25 or greater. As the obesity rate continues to rise, researchers seek an approach that can prevent weight gain or promote weight loss. Some studies suggest that people who eat more dairy products weigh less. Dairy products are a good source of calcium. Obesity / Weight Loss / Fitness Sat, 13 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/153666.php http://www.medicalnewstoday.com/articles/153666.php BACKGROUND: Low-density lipoprotein (LDL) is the so-called "bad cholesterol" often linked to medical problems like heart disease and clogged arteries. Cells in the liver produce a specific receptor that sticks to LDL and removes it from the blood, lowering cholesterol levels. Statin drugs also reduce LDL cholesterol levels by boosting cells' production of the receptor. Cholesterol Fri, 12 Jun 2009 07:00:00 PDT http://www.medicalnewstoday.com/articles/153479.php http://www.medicalnewstoday.com/articles/153479.php A genetic analysis of data from three studies suggests that genetically elevated levels of lipoprotein(a) are associated with an increased risk of heart attack, according to a study in the June 10 issue of JAMA. Myocardial infarction (MI; heart attack) remains a leading cause of illness and death despite targeting of low-density lipoprotein (LDL) cholesterol by statin therapy. Heart Disease Thu, 11 Jun 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/153454.php http://www.medicalnewstoday.com/articles/153454.php A genetic analysis from three studies of people living in Denmark found that those who had higher levels of a cholesterol known as lipoprotein (a) due to genetic reasons were at higher risk of heart attack. Cholesterol Wed, 10 Jun 2009 05:00:00 PDT http://www.medicalnewstoday.com/articles/153298.php http://www.medicalnewstoday.com/articles/153298.php Abbott and AstraZeneca announced today that they have entered into an agreement for AstraZeneca to co-promote Abbott's TRILIPIX® (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote TRILIPIX alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed. Statins Wed, 10 Jun 2009 05:00:00 PDT http://www.medicalnewstoday.com/articles/153299.php http://www.medicalnewstoday.com/articles/153299.php Abbott Park, Illinois (NYSE: ABT) and London, UK - Abbott and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). Cholesterol Wed, 10 Jun 2009 04:00:00 PDT http://www.medicalnewstoday.com/articles/153288.php http://www.medicalnewstoday.com/articles/153288.php Small LDL (sLDL) is the most harmful form of cholesterol! People with small LDL are five times as likely to have cardiovascular disease. However, most laboratories do not test for it. Randox provides an easy to use sLDL test to help assess cardiovascular disease risk. Early identification of predominant sLDL can help clinicians manage patients more effectively through more aggressive treatment. Cardiovascular / Cardiology Tue, 09 Jun 2009 07:00:00 PDT http://www.medicalnewstoday.com/articles/153157.php http://www.medicalnewstoday.com/articles/153157.php Overweight individuals who ate a low-calorie, low-carbohydrate diet high in plant-based proteins for four weeks lost weight and experienced improvements in blood cholesterol levels and other heart disease risk factors, according to a report in the June 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. A high-carbohydrate, low-fat vegetarian diet also resulted in weight loss but without the additional cardiovascular benefits. Obesity / Weight Loss / Fitness Fri, 05 Jun 2009 02:00:00 PDT http://www.medicalnewstoday.com/articles/152693.php http://www.medicalnewstoday.com/articles/152693.php Abbott (NYSE: ABT) and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). Endocrinology Mon, 01 Jun 2009 11:00:00 PDT http://www.medicalnewstoday.com/articles/152113.php http://www.medicalnewstoday.com/articles/152113.php A new pill that contains a potent version of the naturally occurring compound lycopene, a carotenoid found in tomatoes and other fruits and vegetables, was launched today as a new approach to the treatment of high blood cholesterol and atherosclerosis. Cholesterol Fri, 29 May 2009 04:00:00 PDT http://www.medicalnewstoday.com/articles/151885.php http://www.medicalnewstoday.com/articles/151885.php The atherosclerosis vaccine development program by AFFiRiS AG is receiving financial support from the EU's EUROTRANS-BIO call. The respective project is being carried out in cooperation with German company EMC microcollections GmbH. The aim of atherosclerosis vaccination is to increase the amount of "good" high density lipoprotein cholesterol (HDLc) in the blood and thus reduce the occurrence of harmful fatty deposits in the arteries. Cardiovascular / Cardiology Thu, 28 May 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/151624.php http://www.medicalnewstoday.com/articles/151624.php The atherosclerosis vaccine development program by AFFiRiS AG is receiving financial support from the EU's EUROTRANS-BIO call. The respective project is being carried out in cooperation with German company EMC microcollections GmbH. The aim of atherosclerosis vaccination is to increase the amount of "good" high density lipoprotein cholesterol (HDLc) in the blood and thus reduce the occurrence of harmful fatty deposits in the arteries. Cardiovascular / Cardiology Tue, 26 May 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/151324.php http://www.medicalnewstoday.com/articles/151324.php People who take cholesterol-lowering drugs called statins after a stroke may be less likely to have another stroke later, according to research published in the May 26, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology. Those who take statins after a stroke may also be less likely to die within the next 10 years than those who do not take statins. Stroke Tue, 26 May 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/151296.php http://www.medicalnewstoday.com/articles/151296.php People with diabetes who were prescribed the cholesterol-lowering drug fenofibrate reduced their risk of minor amputations by 36 per cent, according to new research. Researchers in Australia, Finland and New Zealand looked at almost 10,000 people aged between 50 and 75 with Type 2 diabetes. About half of them were given fenofibrate while the other half were given placebos. Diabetes Sun, 24 May 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/151153.php http://www.medicalnewstoday.com/articles/151153.php Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) met its primary endpoint, with a 25 percent reduction in LDL cholesterol after 26 weeks of treatment, vs. 3 percent for placebo (p Cholesterol Tue, 19 May 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/150490.php http://www.medicalnewstoday.com/articles/150490.php Essentialis Inc, a clinical stage pharmaceutical company, announced that it met its primary endpoint of statistically significant triglyceride reduction in a 90-patient Phase 2b trial of DCCR in dyslipidemic patients. The study encompassed both patients with very high triglycerides and mixed dyslipidemia and included normal weight, overweight and obese patients presenting with or without hypertension. Cholesterol Mon, 18 May 2009 02:00:00 PDT http://www.medicalnewstoday.com/articles/150400.php http://www.medicalnewstoday.com/articles/150400.php The results of a new survey of 400 UK healthcare professionals, conducted by TNS Healthcare UK and sponsored by Merck Sharp & Dohme Limited and Schering-Plough Limited, reveal that the majority of GPs surveyed (82% of the 100 GPs) believe that the cholesterol indicator (CHD 08) should remain a priority area in the Quality and Outcomes Framework (QOF). Cholesterol Sat, 16 May 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/150261.php http://www.medicalnewstoday.com/articles/150261.php A novel species of bacteria with cholesterol-busting properties has been discovered by scientists at the Universidad Complutense de Madrid, Spain. Dr Oliver Drzyzga and colleagues isolated the new bug, called Gordonia cholesterolivorans, from sewage sludge. Their findings are reported in the current issue of the International Journal of Systematic and Evolutionary Microbiology. Cholesterol Sat, 16 May 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/150204.php http://www.medicalnewstoday.com/articles/150204.php Researchers at the University of California, San Diego have discovered that a complex network of interactions between drugs and the proteins with which they bind can explain adverse drug effects. Their findings suggest that adverse drug effects might be minimized by using single or multiple drug therapies in order to fine-tune multiple off-target interactions. Statins Fri, 08 May 2009 04:00:00 PDT http://www.medicalnewstoday.com/articles/149396.php http://www.medicalnewstoday.com/articles/149396.php Data from the Treating to New Targets (TNT) trial presented at the American Society of Hypertension's Twenty Fourth Annual Scientific Meeting (ASH 2009) show that low blood pressure levels may lead to increased risk of cardiovascular events, including heart attack and stroke. These data supplement previous findings from the TNT trial of atorvastatin showing aggressive LDL cholesterol-lowering reduced cardiovascular events. Hypertension Thu, 30 Apr 2009 05:00:00 PDT http://www.medicalnewstoday.com/articles/148273.php http://www.medicalnewstoday.com/articles/148273.php Reaching optimal levels for cholesterol and high blood pressure in people who've had a stroke adds up to prevent a second stroke or heart attack, according to a study presented as part of the Late-breaking Science Program at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 - May 2, 2009. Researchers looked at four risk factors for stroke: high LDL cholesterol, low HDL cholesterol, high triglycerides, and high blood pressure. Stroke